About Impact Therapeutics Limited
Data last updated:
Impact Therapeutics Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 29 December 2010 and has been in existence for over 16 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U51909MH2010PLC211564. Its GSTIN is 27AAHCM0461F1ZO (Maharashtra).
The company has an authorised share capital of ₹15.1 Cr and a paid-up capital of ₹15.1 Cr. It was formerly known as Miles Tradexim Private Limited. It is led by directors including Ambarish Chatterjee and Pooja Rajan Ambure.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 1004 10th Floor Lodha Supremus Powai Saki Vihar Road Opp Mtnl Office Powai, Mumbai, Maharashtra, India – 400072.
As per the financials filed for FY 2024, the company reported a revenue of ₹1,499.49 Cr, a growth of 75% compared to the previous year. For the same year it recorded a net profit of ₹59.3 Cr (net margin 4%) and EBITDA of ₹86.38 Cr (EBITDA margin 5.8%). Revenue has grown at a compounded annual rate (CAGR) of 51% over three years and 39% over five years.
Its group structure includes 1 subsidiary.
As per MCA filings, the company has open charges of ₹128 Cr and satisfied charges of ₹15 Cr on record. Court records list 1 case involving the company, including 1 filed against it; 1 case is pending. The company has 9 deals on record (6 secondary share transfers, 2 rights issues, 1 funding round), with disclosed funding of ₹61.58 Cr; the latest was in March 2024. Its 10 peer companies in the Pharma industry (API Manufacturers) are compared by revenue, 5 larger and 5 smaller; the largest is Morepen Laboratories Limited with revenue of ₹1,829.94 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website medecdragon.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered Address1004 10th Floor Lodha Supremus Powai Saki Vihar Road Opp Mtnl Office Powai, Mumbai, Maharashtra, India – 400072
- IndustryPharma, API Manufacturers
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Impact Therapeutics Limited
The main business activity of Impact Therapeutics is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Impact Therapeutics Limited FY 2024 filings available
Impact Therapeutics Limited reported revenue of ₹1,499.49 Cr (up 75% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR) of Impact Therapeutics Limited
Revenue has grown at a compounded annual rate (CAGR) of 39% over five years, including 75% growth in the latest year. EBITDA rose 29% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Impact Therapeutics Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹86.38 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹59.3 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Impact Therapeutics Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 5.8% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 4% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Impact Therapeutics are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Impact Therapeutics Limited
Impact Therapeutics Limited is compared with the companies closest to it by revenue in the Pharma industry (API Manufacturers). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Morepen Laboratories Limited Listed | ₹1,829.94 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | Himachal Pradesh, India |
| MSN Pharmachem Private Limited | ₹1,716.51 Cr (FY 2024) | •••• | •••• | 40.0% | •••• | Hyderabad, Telangana, India |
| Indoco Remedies Limited Listed | ₹1,670.37 Cr (FY 2025) | •••• | •••• | -9.0% | •••• | Mumbai, Maharashtra, India |
| Dishman Pharmaceuticals and Chemicals Limited | ₹1,622.59 Cr (FY 2016) | •••• | •••• | -3.0% | •••• | Ahmedabad, Gujarat, India |
| Viyash Scientific Limited Listed | ₹1,566.06 Cr (FY 2025) | •••• | •••• | 13.0% | •••• | Hyderabad, Telangana, India |
| Impact Therapeutics Limited this company | ₹1,499.49 Cr (FY 2024) | •••• | •••• | 75.0% | •••• | Mumbai, Maharashtra, India |
| Virchow Petrochemical Private Limited | ₹1,499.36 Cr (FY 2025) | •••• | •••• | -7.0% | •••• | Patancheru, Telangana, India |
| Neuland Laboratories Ltd. Listed | ₹1,497.35 Cr (FY 2025) | •••• | •••• | -5.0% | •••• | Hyderabad, Telangana, India |
| Viyash Life Sciences Private Limited | ₹1,482.68 Cr (FY 2025) | •••• | •••• | 9.0% | •••• | Hyderabad, Telangana, India |
| Virchow Laboratories Limited | ₹1,479.64 Cr (FY 2025) | •••• | •••• | 2.0% | •••• | Telangana, India |
| Teva Api India Private Limited | ₹1,456.07 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | Mumbai, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below Impact Therapeutics by revenue in the Pharma industry (API Manufacturers), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Impact Therapeutics Limited
Impact Therapeutics Limited is audited by CHATURVEDI & PATEL for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| CHATURVEDI & PATEL | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Impact Therapeutics Limited
Impact Therapeutics has 3 current directors and 18 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ambarish Chatterjee | Director | 25 Jan 2024 | 2 Years 8 Months | Current |
| Pooja Rajan Ambure Also directs: Ahimsa Industries Limited | Director | 25 Jan 2024 | 2 Years 8 Months | Current |
| Rakesh Grihpati Singh | Additional Director | 15 Jul 2025 | 1 Years 2 Months | Current |
Ownership and Shareholding of Impact Therapeutics Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Impact Therapeutics Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Jun 2023 | Axis Bank Limited | ₹20 Cr | Open |
| 14 Feb 2023 | Axis Bank Limited | ₹20 Cr | Open |
| 16 Feb 2022 | Axis Bank Limited | ₹88 Cr | Open |
| 11 Apr 2025 | Hdfc Bank Limited | ₹15 Cr | Satisfied |
Total charge records: 4 View all charges
Deals & Funding of Impact Therapeutics Limited
Impact Therapeutics Limited has 9 deals on record (6 secondary share transfers, 2 rights issues, 1 funding round), with disclosed funding of ₹61.58 Cr; the latest was in March 2024.
Deals on record (5 of 9)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2024 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: 2 individuals |
| Jan 2023 | Rights issue | ₹13.1 Cr | Investors: an individual |
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Apr 2020 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
| Feb 2019 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
Full deal history
All 9 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Impact Therapeutics Limited
Impact Therapeutics Limited has 1 court case on record: 1 filed against it. All case is pending. Status as checked on 21 Sep 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 1 | 1 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Thane, Maharashtra | Civil suit | Filed against the company by Union of India Income Tax Department | Pending |
Full case history
All 1 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Impact Therapeutics Limited
Employment history and EPFO contributions of people linked to Impact Therapeutics.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Group Structure of Impact Therapeutics Limited
Impact Therapeutics has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares Held |
|---|---|---|
| Medec Infra Private Limited | U28990MH2021PTC360696 | Locked |
Showing major subsidiaries. Total: 1.
Name History of Impact Therapeutics Limited
Impact Therapeutics has undergone 2 name changes throughout its history. The company was previously known as Miles Tradexim Private Limited, and Impact Therapeutics Limited. The current legal name is Impact Therapeutics Limited.
| Company Name | Status |
|---|---|
| Impact Therapeutics Limited | Current |
| Miles Tradexim Private Limited | Previous |
CIN History of Impact Therapeutics Limited
Impact Therapeutics has one previous CIN (Corporate Identification Number): U51909MH2010PTC211564. The current CIN is U51909MH2010PLC211564, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U51909MH2010PLC211564 | Current |
| U51909MH2010PTC211564 | Previous |
Recent Activity on Impact Therapeutics Limited
Impact Therapeutics Limited has 22 board changes on record since 2017: 4 appointments and 18 cessations. The latest: Rakesh Grihpati Singh was appointed as Additional Director on 15 Jul 2025.
20 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Impact Therapeutics Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Impact Therapeutics Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Impact Therapeutics Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Impact Therapeutics Limited
Impact Therapeutics has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAHCM0461F1ZO | Maharashtra | Active | 03 Jan 2018 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Impact Therapeutics Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Impact Therapeutics Limited
Impact Therapeutics is an active public limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 29 December 2010 (16+ years old) and is registered under CIN U51909MH2010PLC211564.
Impact Therapeutics reported revenue of ₹1,499.49 Cr for FY 2024 (up 75% YoY).
Impact Therapeutics has 3 current directors:
- Ambarish Chatterjee - Director
- Pooja Rajan Ambure - Director
- Rakesh Grihpati Singh - Additional Director
Impact Therapeutics reported a net profit of ₹59.3 Cr (net margin 4%) and EBITDA of ₹86.38 Cr (EBITDA margin 5.8%) for FY 2024, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Impact Therapeutics is 51% over three years and 39% over five years. In the latest year (FY 2024) revenue rose 75%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Impact Therapeutics is 27AAHCM0461F1ZO, registered in Maharashtra.
The CIN (Corporate Identification Number) of Impact Therapeutics is U51909MH2010PLC211564. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Impact Therapeutics has 1 court case on record: 1 filed against it. 1 is pending.
Impact Therapeutics was incorporated on 29 December 2010, making it 16+ years old. It is registered with the Registrar of Companies, Mumbai.
Impact Therapeutics has 9 deals on record (6 secondary share transfers, 2 rights issues, 1 funding round), with disclosed funding of ₹61.58 Cr; the latest was in March 2024.
The peers of Impact Therapeutics by revenue are Morepen Laboratories Limited, MSN Pharmachem Private Limited, Indoco Remedies Limited, Dishman Pharmaceuticals and Chemicals Limited, Viyash Scientific Limited and 5 more, all in the Pharma industry (API Manufacturers).